Emmaus Life Sciences Inc (EMMA)
OTHER OTC:EMMA
Total Valuation
Emmaus Life Sciences has a market cap or net worth of $701.88K. The enterprise value is $31.07M.
Market Cap$701.88K
Enterprise Value$31.07M
Share Statistics
Emmaus Life Sciences has 70,188,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,188,260
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Emmaus Life Sciences’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is -1.23%.
Return on Equity (ROE)0.12
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-1.23%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee366.26K
Profits Per Employee-220.35K
Employee Count34
Asset Turnover0.58
Inventory Turnover0.55
Valuation Ratios
The current PE Ratio of Emmaus Life Sciences is ―. Emmaus Life Sciences’s PEG ratio is -0.00556.
PE Ratio―
PS Ratio0.07
PB Ratio-0.01
Price to Fair Value-0.01
Price to FCF-69.38
Price to Operating Cash Flow-58.80
PEG Ratio-0.00556
Income Statement
In the last 12 months, Emmaus Life Sciences had revenue of 12.45M and earned -7.49M in profits. Earnings per share was -0.12.
Revenue12.45M
Gross Profit11.60M
Operating Income231.00K
Pretax Income-7.48M
Net Income-7.49M
EBITDA-310.00K
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was -11.00K and capital expenditures -1.00K, giving a free cash flow of -12.00K billion.
Operating Cash Flow-11.00K
Free Cash Flow-12.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Emmaus Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta58.72
52-Week Price Change-37.50%
50-Day Moving Average0.01
200-Day Moving Average0.01
Relative Strength Index (RSI)44.03
Average Volume (3m)112.45K
Important Dates
Emmaus Life Sciences upcoming earnings date is May 20, 2026, Before Open (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Emmaus Life Sciences as a current ratio of 0.11, with Debt / Equity ratio of -51.19%
Current Ratio0.11
Quick Ratio0.09
Debt to Market Cap37.00
Net Debt to EBITDA-98.17
Interest Coverage Ratio0.03
Taxes
In the past 12 months, Emmaus Life Sciences has paid 9.00K in taxes.
Income Tax9.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Emmaus Life Sciences EV to EBITDA ratio is -100.85, with an EV/FCF ratio of -2.61K.
EV to Sales2.51
EV to EBITDA-100.85
EV to Free Cash Flow-2.61K
EV to Operating Cash Flow-2.84K
Balance Sheet
Emmaus Life Sciences has $2.13M in cash and marketable securities with $32.56M in debt, giving a net cash position of -$30.43M billion.
Cash & Marketable Securities$2.13M
Total Debt$32.56M
Net Cash-$30.43M
Net Cash Per Share-$0.43
Tangible Book Value Per Share-$0.99
Margins
Gross margin is 93.12%, with operating margin of 1.85%, and net profit margin of -60.16%.
Gross Margin93.12%
Operating Margin1.85%
Pretax Margin-60.09%
Net Profit Margin-60.16%
EBITDA Margin-2.49%
EBIT Margin-2.80%
Analyst Forecast
The average price target for Emmaus Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-41.78%
EPS Growth Forecast-101.59%